GlobeStar Therapeutics CorpOTC Pink - Current Information:GSTC
- LAST PRICE0.0009
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0008 / 0.0009
- Day Range
- 52 Week Range
- Volume39,911
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GSTC |
|---|---|---|
| 10:46 ET | 28800 | 0.0008 |
| 02:54 ET | 11111 | 0.0009 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
GlobeStar Therapeutics Corp | 1.0M | -0.4x | --- |
Evelo Biosciences Inc | 937.1K | 0.0x | --- |
LadRx Corp | 1.2M | 4.0x | --- |
Agentix Corp | 1.3M | -1.3x | --- |
Capstone Holding Corp | 819.6K | -0.8x | --- |
Regenicin Inc | 767.4K | -0.8x | --- |
Company Information
GlobeStar Therapeutics Corporation (GlobeStar Therapeutics) is a clinical-stage pharmaceutical company. The Company is focused on introducing a patented formulation of drugs for the treatment of Multiple Sclerosis and other neurodegenerative diseases. The Company owns the global license from the inventors, who are based in Italy. The Company has acquired a license for a patented method of treating neurodegenerative diseases such as Multiple Sclerosis by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration and treating neurodegeneration. GlobeStar Therapeutics is initiating discussions with the Food and Drug Administration (FDA) on clinical trial design in preparation for FDA submission and approval pathway.
Contact Information
- Headquarters
- 719 Jadwin AvenueRICHLAND, WA, United States 99352
- Phone
- 509-531-1671
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer, Principal Executive Officer, Company Secretary
- James Katzaroff
- Chief Financial Officer, Treasurer, Principal Financial Officer
- Robert Chicoski
- Independent Director
- William Farley
- Independent Director
- Steven Penderghast
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.2B |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.56 |
EPS | $0.00 |
Book Value | $0.00 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
